{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-106464","form_type":"8-K","ticker":"VBIO","cik":"0001787740","company_name":"Valion Bio, Inc.","filed_at":"2024-09-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.529806+00:00","generated_at":"2026-05-31T04:58:06.855695+00:00","sec_items":["1.01","5.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Tivic Health enters ATM equity facility up to $10M; appoints Lisa Wolf as interim CFO","bullets":["Equity Distribution Agreement with Maxim Group for at-the-market sales of common stock up to $10M aggregate offering price; current baby shelf limit $1.44M.","Maxim receives 3.0% commission; Tivic reimburses up to $40K expenses plus $5K per bringdown.","Kimberly Bambach resigns as interim CFO effective Oct 1, 2024; remains advisor for strategic transactions.","Lisa Wolf appointed interim CFO effective Oct 1, 2024; paid $275/hour as non-employee consultant; has served Tivic since June 2022 via Murdock Martell.","Wolf brings 30 years experience, including CAO at Resonant (RESN) and CPA at Arthur Andersen."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-106464","json":"https://secwatch.observer/filing/0000950170-24-106464.json","markdown":"https://secwatch.observer/filing/0000950170-24-106464.md","text":"https://secwatch.observer/filing/0000950170-24-106464.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787740/000095017024106464/0000950170-24-106464-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787740/000095017024106464/tivc-20240912.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T04:58:06.855695+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bf94e9a5f3","claim":"Kimberly Bambach departed as interim Chief Financial Officer at Valion Bio, Inc..","evidence_excerpt":"On September 12, 2024, Kimberly Bambach tendered her resignation from her role as interim Chief Financial Officer of the Company, effective October 1, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787740/000095017024106464/0000950170-24-106464-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resignation"},{"label":"Role","value":"interim Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"c43c55f471","claim":"Lisa Wolf was appointed as interim Chief Financial Officer and Principal Financial and Principal Accounting Officer at Valion Bio, Inc..","evidence_excerpt":"Effective October 1, 2024, Lisa Wolf has been appointed as the Company’s new interim Chief Financial Officer and Principal Financial and Principal Accounting Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787740/000095017024106464/0000950170-24-106464-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"interim Chief Financial Officer and Principal Financial and Principal Accounting Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}